All News

Treatments before surgery for rectal adenocarcinoma, a type of rectal cancer, have increased and correlated with preservative surgeries and improved overall survival in the last 16 years, though improvements may still be needed for disease screening, an expert said.

When I was asked to speak to a youth service club about my cancer, they asked some meaningful questions, making me take stock of my experience.

Treatment with tovorafenib led to a 64% overall response rate in patients with recurrent or progressive pediatric low-grade glioma, study findings showed.

Although there is no cure for myeloma, the prognosis can be good if doctors catch it early.

The risk for psychiatric disorders increased for spouses of patients with cancer compared with those whose partners did not have cancer.

CURE® surveyed its audience to learn how they celebrate milestones in their experiences with cancer, if they do at all. Here’s what they have to say.

As a cancer survivor, major medical appointments cause a great deal of stress. It took my dog throwing up to make me snap out of it.

TAVT-45, a drug that can be mixed with juice or water, showed similar efficacy in treating metastatic castration-resistant prostate cancer as Zytiga.

If you were to meet Dr. Sundar Jagannath in a crowded room, you would not assume that he is one of the greatest myeloma doctors of all time.

Through Dr. Frits van Rhee's patient care and research, he has made a significant impact on improving the lives of those affected by multiple myeloma.

Fighting for something I believe in was worth it, especially since it came to my health after cancer.

I find myself enormously inadequate to fully explain why I think this lady, my wife, should be selected as a Multiple Myeloma Hero, but whether she is or not, she is my hero.

Imetelstat improves eight- and 24-week transfusion independence in patients with low-risk myelodysplastic syndrome, according to topline study results.

Investigators have administered Keytruda and ONC-392 the first patients with platinum resistant ovarian cancer.

As a cancer survivor, the COVID-19 pandemic continues to affect me and force me to miss activities — and people — I love.

From tennis star Martina Navratilova’s two cancer diagnoses to First Lady Jill Biden undergoing Mohs surgery to have a suspicious lesion removed and musician deaths, here’s what’s happening in the cancer space this week.

When I met my myeloma care team, something just clicked, and I knew I was in good hands.

In 2023, instead of looking over my shoulder to see how cancer has invaded every aspect of my life, I’m vowing to face forward. No fear. No uncertainty. No what-ifs.

Patients with breast cancer who receive mastectomies and are discharged the same day report similar levels of satisfaction to those who are admitted, but more research is needed, explained an expert.

I’ve heard the phrase, “don’t waste your cancer,” as a way to encourage survivors to tell their stories and donate to nonprofits.

A phase 2 trial evaluating EVX-01 plus Keytruda (pembrolizumab) in patients with metastatic melanoma may continue, the FDA said.

Even with all he has already done, Dr. Landgren continues to study the progression of multiple myeloma, with the goal of stopping progression and finding a cure.

A novel three-drug combination bested standard-of-care regimens for patients with human papillomavirus-related cancers, according to phase 2 study results.

Now that I’m six years out of my breast cancer treatment, people assume that I’m better and lack empathy. However, my anxiety is still high.

My local cancer wellness center offered a singing bowls session, which I found incredibly relaxing.

We need to learn more about how to potentially lessen toxins' effects on people's lives.

For over 20 years, Dr. Brian Berryman has been a tireless advocate and compassionate care provider for those affected by multiple myeloma.

Promising early clinical data about the drugs ERAS-007 and ERAS-601 has led to a trial studying the combination of the two drugs in treating patients with RAS/MAPK pathway-driven cancers.